---
title: 'The Niche Episode 081 – CSL + Vifor, Oracle + Cerner, Calliditas, Omega Funds'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-081-csl-vifor-oracle-cerner-calliditas-omega-funds'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-12-21'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 081 – CSL + Vifor, Oracle + Cerner, Calliditas, Omega Funds

Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new yearFind out more athttps://thenichepod.comStory ReferencesCSL + ViforOracle + CernerCalliditasOmegaAbout the ShowThe Niche Podcast brings you interviews w…

## Summary

Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new year

**Find out more at
**[https://thenichepod.com](https://thenichepod.com/)

**Story References
**[CSL + Vifor
](https://www.biospace.com/article/csl-tenders-offer-to-buy-vifor-pharma-for-11-7-billion/?s=79)[Oracle + Cerner
](https://www.oracle.com/news/announcement/oracle-buys-cerner-2021-12-20/)[Calliditas
](https://www.biospace.com/article/calliditas-scores-milestone-first-approval-for-igan-proteinuria-drug/?s=74)[Omega](https://www.biospace.com/article/omega-funds-new-fund-has-650-million-to-invest-in-life-science-companies/?s=75)[**
**](https://www.biospace.com/article/alvotech-advances-efforts-into-biosimilar-drugs-with-oaktree-merger/?s=79)
**About the Show**
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.